Nidanilimab
Nidanilimab Basic information
- Product Name:
- Nidanilimab
- Synonyms:
-
- Nidanilimab
- Nadunolimab
- Research Grade Nadunolimab(DHJ63401)
- Nadunolimab (anti-IL-1 RAcP)
- CAN04
- Research Grade Nadunolimab
- CAS:
- 2171061-85-9
- MW:
- 0
- Mol File:
- Mol File
Nidanilimab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Nidanilimab Usage And Synthesis
Uses
Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) [1][2].
in vivo
Nidanilimab (CAN04; 10 mg/kg; i.p.; nude C57Bl/6 mice) increases the efficacy of Cisplatin (HY-17394)/Gemcitabine (HY-17026) and Carboplatin (HY-17393)/Gemcitabine (HY-17026), two commonly used platinum-based chemotherapies[1].
| Animal Model: | Nude C57Bl/6 mice with LU2503 NSCLC PDX model[1] |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection |
| Result: | Displayed a significantly stronger anti-tumor effect compared to isotype control with chemotherapy. |
IC 50
IL-1α; IL-1β
References
[1] Millrud CR, et, al. The anti-IL1RAP antibody CAN04 increases tumor sensitivity to platinum-based chemotherapy.
[2] Rydberg Millrud C, et, al. Blockade of IL-1α and IL-1β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy. Cancer Immunol Immunother. 2022 Aug 29. DOI:10.1007/s00262-022-03277-3
NidanilimabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 4008200310
- marketing@tsbiochem.com